nach oben

Erschienen in:

01.11.2011 | Article

Increased neuronal nitric oxide synthase dimerisation is involved in rat and human pancreatic beta cell hyperactivity in obesity

verfasst von: K. Mezghenna, P. Pomiès, A. Chalançon, F. Castex, J. Leroy, N. Niclauss, B. Nadal, L. Cambier, C. Cazevieille, P. Petit, R. Gomis, T. Berney, R. Gross, A. D. Lajoix

Erschienen in: Diabetologia | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Pancreatic beta cell hyperactivity is known to occur in obesity, particularly in insulin-resistant states. Our aim was to investigate whether changes in neuronal nitric oxide synthase (nNOS) function affect beta cell compensation in two relevant models: the Zucker fa/fa rats and pancreatic islets from obese humans.

Methods

Glucose-induced insulin response was evaluated in the isolated perfused rat pancreas and in human pancreatic islets from obese individuals. Expression of nNOS (also known as NOS1) and subcellular localisation of nNOS were studied by quantitative RT-PCR, immunoblotting, immunofluorescence and electron microscopy.

Results

Pancreatic beta cells from Zucker fa/fa rats and obese individuals were found to be hyper-responsive to glucose. Pharmacological blockade of nNOS was unable to modify beta cell response to glucose in fa/fa rats and in islets from obese individuals, suggesting an abnormal control of insulin secretion by the enzyme. In both cases, nNOS activity in islet cell extracts remained unchanged, despite a drastic increase in nNOS protein and an enhancement in the dimer/monomer ratio, pointing to the presence of high amounts of catalytically inactive enzyme. This relative decrease in activity could be mainly related to increases in islet asymmetric dimethyl-arginine content, an endogenous inhibitor of nNOS activity. In addition, mitochondrial nNOS level was decreased, which contrasts with a strongly increased association with insulin granules.

Conclusions/interpretation

Increased nNOS production and dimerisation, together with a relative decrease in catalytic activity and relocalisation, are involved in beta cell hyperactivity in insulin-resistant rats but also in human islets isolated from obese individuals.

Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802–1812PubMedCrossRef

Phillips MS, Liu Q, Hammond HA et al (1996) Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet 13:18–19PubMedCrossRef

Pick A, Clark J, Kubstrup C et al (1998) Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47:358–364PubMedCrossRef

Chan CB, MacPhail RM, Mitton K (1993) Evidence for defective glucose sensing by islets of fa/fa obese Zucker rats. Can J Physiol Pharmacol 71:34–39PubMedCrossRef

Ferrannini E, Camastra S, Gastaldelli A et al (2004) Beta-cell function in obesity: effects of weight loss. Diabetes 53(Suppl 3):S26–S33PubMedCrossRef

Chan CB, Pederson RA, Buchan AM, Tubesing KB, Brown JC (1984) Gastric inhibitory polypeptide (GIP) and insulin release in the obese Zucker rat. Diabetes 33:536–542PubMedCrossRef

Liu YQ, Jetton TL, Leahy JL (2002) β-Cell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats. J Biol Chem 277:39163–39168PubMedCrossRef

Nolan CJ, Leahy JL, Delghingaro-Augusto V et al (2006) Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling. Diabetologia 49:2120–2130PubMedCrossRef

Moncada S, Palmer RM, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109–142PubMed

10.

Lajoix AD, Reggio H, Chardes T et al (2001) A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells controls insulin secretion. Diabetes 50:1311–1323PubMedCrossRef

11.

Lajoix AD, Pugniere M, Roquet F et al (2004) Changes in the dimeric state of neuronal nitric oxide synthase affect the kinetics of secretagogue-induced insulin response. Diabetes 53:1467–1474PubMedCrossRef

12.

Salehi A, Meidute Abaraviciene S, Jimenez-Feltstrom J, Ostenson CG, Efendic S, Lundquist I (2008) Excessive islet NO generation in type 2 diabetic GK rats coincides with abnormal hormone secretion and is counteracted by GLP-1. PLoS One 14:e2165CrossRef

13.

Bucher P, Mathe Z, Morel P et al (2005) Assessment of a novel two-component enzyme preparation for human islet isolation and transplantation. Transplantation 79:91–97PubMedCrossRef

14.

Klatt P, Schmidt K, Lehner D, Glatter O, Bachinger HP, Mayer B (1995) Structural analysis of porcine brain nitric oxide synthase reveals a role for tetrahydrobiopterin and l-arginine in the formation of an SDS-resistant dimer. EMBO J 14:3687–3695PubMed

15.

Hayashi Y, Nishio M, Naito Y et al (1999) Regulation of neuronal nitric-oxide synthase by calmodulin kinases. J Biol Chem 274:20597–20602PubMedCrossRef

16.

Sennequier N, Wolan D, Stuehr DJ (1999) Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem 274:930–938PubMedCrossRef

17.

Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Ribes G (1995) Alterations of insulin response to different beta cell secretagogues and pancreatic vascular resistance induced by N omega-nitro-l-arginine methyl ester. Br J Pharmacol 116:1965–1972PubMed

18.

Jetton TL, Lausier J, LaRock K et al (2005) Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes 54:2294–2304PubMedCrossRef

19.

Chan CB, MacPhail RM, Sheu L, Wheeler MB, Gaisano HY (1999) Beta-cell hypertrophy in fa/fa rats is associated with basal glucose hypersensitivity and reduced SNARE protein expression. Diabetes 48:997–1005PubMedCrossRef

20.

Polonsky KS, Given BD, van Cauter E (1988) Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81:442–448PubMedCrossRef

21.

Campbell PJ, Gerich JE (1990) Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab 70:1114–1118PubMedCrossRef

22.

Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100:1166–1173PubMedCrossRef

23.

Morley JE, Mattammal MB (1996) Nitric oxide synthase levels in obese Zucker rats. Neurosci Lett 209:137–139PubMedCrossRef

24.

Carbone DL, Moreno JA, Tjalkens RB (2008) Nuclear factor kappa-B mediates selective induction of neuronal nitric oxide synthase in astrocytes during low-level inflammatory stimulation with MPTP. Brain Res 1217:1–9PubMedCrossRef

25.

Liu X, Buffington JA, Tjalkens RB (2005) NF-kappaB-dependent production of nitric oxide by astrocytes mediates apoptosis in differentiated PC12 neurons following exposure to manganese and cytokines. Brain Res Mol Brain Res 141:39–47PubMedCrossRef

26.

Karacay B, Li G, Pantazis NJ, Bonthius DJ (2007) Stimulation of the cAMP pathway protects cultured cerebellar granule neurons against alcohol-induced cell death by activating the neuronal nitric oxide synthase (nNOS) gene. Brain Res 1143:34–45PubMedCrossRef

27.

Dunbar AY, Kamada Y, Jenkins GJ, Lowe ER, Billecke SS, Osawa Y (2004) Ubiquitination and degradation of neuronal nitric-oxide synthase in vitro: dimer stabilization protects the enzyme from proteolysis. Mol Pharmacol 66:964–969PubMedCrossRef

28.

Stuhlinger MC, Abbasi F, Chu JW et al (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420–1426PubMedCrossRef

29.

Konukoglu D, Uzun H, Firtina S et al (2007) Plasma adhesion and inflammation markers: asymmetrical dimethyl-l-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients. Obes Surg 17:672–678PubMedCrossRef

30.

Leiper J, Vallance P (1999) Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43:542–548PubMedCrossRef

31.

Lajoix AD, Badiou S, Peraldi-Roux S et al (2006) Protein inhibitor of neuronal nitric oxide synthase (PIN) is a new regulator of glucose-induced insulin secretion. Diabetes 55:3279–3288PubMedCrossRef

32.

Jaffrey SR, Snyder SH (1996) PIN: an associated protein inhibitor of neuronal nitric oxide synthase. Science 274:774–777PubMedCrossRef

33.

Benashski SE, Harrison A, Patel-King RS, King SM (1997) Dimerization of the highly conserved light chain shared by dynein and myosin V. J Biol Chem 272:20929–20935PubMedCrossRef

34.

Varadi A, Tsuboi T, Rutter GA (2005) Myosin Va transports dense core secretory vesicles in pancreatic MIN6 beta-cells. Mol Biol Cell 16:2670–2680PubMedCrossRef

35.

Ivarsson R, Jing X, Waselle L, Regazzi R, Renstrom E (2005) Myosin 5a controls insulin granule recruitment during late-phase secretion. Traffic 6:1027–1035PubMedCrossRef

36.

Bindokas VP, Kuznetsov A, Sreenan S, Polonsky KS, Roe MW, Philipson LH (2003) Visualizing superoxide production in normal and diabetic rat islets of Langerhans. J Biol Chem 278:9796–9801PubMedCrossRef

37.

Nisoli E, Clementi E, Paolucci C et al (2003) Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299:896–899PubMedCrossRef

38.

Schild L, Jaroscakova I, Lendeckel U, Wolf G, Keilhoff G (2006) Neuronal nitric oxide synthase controls enzyme activity pattern of mitochondria and lipid metabolism. FASEB J 20:145–147PubMed

39.

Brown GC, Cooper CE (1994) Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett 356:295–298PubMedCrossRef

40.

Neidlinger NA, Odorico JS, Sollinger HW, Fernandez LA (2008) Can ‘extreme’ pancreas donors expand the donor pool? Curr Opin Organ Transplant 13:67–71PubMedCrossRef

Titel: Increased neuronal nitric oxide synthase dimerisation is involved in rat and human pancreatic beta cell hyperactivity in obesity
verfasst von: K. Mezghenna
P. Pomiès
A. Chalançon
F. Castex
J. Leroy
N. Niclauss
B. Nadal
L. Cambier
C. Cazevieille
P. Petit
R. Gomis
T. Berney
R. Gross
A. D. Lajoix
Publikationsdatum: 01.11.2011
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 11/2011
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-011-2264-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2011

Deletion of platelet-derived growth factor receptor-β improves diabetic nephropathy in Ca2+/calmodulin-dependent protein kinase IIα (Thr286Asp) transgenic mice

Trends in population attributable fraction of acute coronary syndrome and ischaemic stroke due to diabetes in Finland

Transcriptomes of the major human pancreatic cell types

Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography the Silent Diabetes Study

High serum potassium levels after using losartan can reflect more severe renal disease